ArticleLe Mali medical2025
[Renal Damage In Sickle Cell Disease: The Experience Of A Sickle Cell Reference Center In Sub-Saharan Africa].
Article in Le Mali medical, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: renal damage, often due to impaired glomerular function, is a progressive complication associated with high mortality in sickle cell disease. Few studies report on this complication in the context of organized care in sub-Saharan Africa. Objective: to describe renal damage in sickle-cell patients attending in sickle-cell referral center in sub-Saharan Africa. Patients and Methods: a descriptive and analytical study with retrospective data collection was carried out from March 2010 to March 2017, at the «Centre de Recherche et de Lutte contre la Drépanocytose» of Bamako, Mali. Results: 125 sickle cell disease patients, including 70 SS, 43 SC, 10 Sβ+thalassemics and 2 Sβ°thalassemics, distributed between 67 women and 58 men with a mean age of 33.03 ± 15.53 years, were identified. Renal damage was documented by sickle cell nephropathy (84.8%), CKD (10.4%) and hematuria (4.8%); it was significantly associated with a history of hypertension, diabetes or non-steroidal antiinflammatory drugs use (p < 0.05), but was not observed in patients with fœtal hemoglobin > 20%. Five patients (4%) were on chronic kidney dialysis. Conclusion: the precocity and high frequency of renal damage in sickle-cell patients in sub-Saharan Africa call for studies to identify the risk factors for this complication in a cohort of sickle-cell patients followed up from birth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.